VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | ECHELON-1 trial updates: overall survival data

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares some updates on the ECHELON-1 trial (NCT01712490), drawing focus on the recent overall survival data that has been reported. Dr Collins highlights the importance of this data and further discusses the need to investigate the application of this treatment approach to better understand the overall survival and implications for Hodgkin lymphoma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.


Honoraria: Roche, Takeda, Gilead, Pfizer, MSD, Celleron, ADC Therapeutics, Incyte, Beigene. Research funding: BMS, MSD, Celleron, Amgen, BMS

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter